Old and new anticoagulant drugs: A minireview

Annals of Medicine

Volumn 43, Issue 2, 2011, Pages 116-123

  Mannucci, Pier Mannuccio ^a   Franchini, Massimo ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Cardiovascular disease; dabigatran; factor Xa inhibitors; fondaparinux; low molecular weight heparins; rivaroxaban; thrombin inhibitors; thromboembolism; unfractionated heparin; warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTIDOTE; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; DABIGATRAN; DABIGATRAN ETEXILATE; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ARTICLE; CORONARY ARTERY THROMBOSIS; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HALF LIFE TIME; HEART ATRIUM FIBRILLATION; HEPARIN INDUCED THROMBOCYTOPENIA; HIP ARTHROPLASTY; HUMAN; ISCHEMIC HEART DISEASE; KNEE ARTHROPLASTY; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG DESIGN; HEPARIN; HUMANS; THROMBOEMBOLISM; WARFARIN;

EID: 79951568921     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2010.539250     Document Type: Article

References (38)

1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifi able risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-52. (Pubitemid 39208455)
2. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. Risk factors for ischaemic and intracere-bral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112-23.
3. Franchini M, Mannucci PM. A new era for anticoagulants. Eur J Intern Med. 2009;20:562-8.
4. Mannucci PM. The start of a new era for new antithrombotic drugs. Pathophysiol Haemost Thromb. 2010;137(Suppl 1): P1-A177.
5. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrom-botic and Thrombolytic Therapy. Chest. 2004;126(3): 133S-203S.
6. Weitz JL. Low-molecular-weight heparins. N Engl J Med. 1997;337:688-98.
7. Fareed J, Hoppensteadt DA, Fareed D, Demir M, Wahi R, Clarke M, et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost. 2008;34:58-73. (Pubitemid 351640882)
8. Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Haemost. 2008;34:39-57. (Pubitemid 351640881)
9. Hoppensteadt DA, Jeske W, Walenga J, Fareed J. The future of anticoagulation. Semin Respir Crit Care Med. 2008;29: 90-100.
10. Mannucci PM, Poller L. Venous thrombosis and anticoagulant therapy. Br J Haematol. 2001;114:258-70. (Pubitemid 32762223)
11. Bates SM, Weitz JI. New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin. Br J Pharmacol. 2005;14:1017-28. (Pubitemid 40592999)
12. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists. Chest. 2008;133:160S-98S.
13. Petitou M, Duchaussoy P, Herbert JM, Duc G, El Hajji M, Branellec JF, et al. The synthetic pentasaccharide fonda-parinux: fi rst in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. Semin Thromb Haemost. 2002;28:393-402. (Pubitemid 34971927)
14. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants. Chest. 2008;133: 141S-59S.
15. Hirsh J, O ' Donnell M, Eikelboom JW. Beyond unfraction-ated heparin and warfarin: current and future advances. Circulation. 2007;116:552-60. (Pubitemid 47450264)
16. Warkentin TE, Greinacher A. Heparin-induced thrombocy-topenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest . 2004;12 6( 3 Suppl ) :311S-37S. (Pubitemid 39297959)
17. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest . 2004;12 6( 3 ) :338S-400S. (Pubitemid 39302602)
18. Agrawal YK, Vaidya H, Bhatt H, Manna K, Brahmkshatriya P. Recent advances in the treatment of thromboembolic diseases: venous thromboembolism. Med Res Rev. 2007;27: 891-914. (Pubitemid 350041545)
19. B ü ller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboem-bolic disease: the Seventh ACCP Conference on Antithrom-botic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl ) : 401S-28S.
20. Harrington RA, Becker RC, Ezekowitz M, Meade TW, O ' Connor CM, Vorchheimer DA, et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):513S-48S. (Pubitemid 39302604)
21. Menon V, Harrington RA, Hochman JS, Cannon CP, Goodman SD, Wilcox RG, et al. Thrombolysis and adjunc-tive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):549S-75S . (Pubitemid 39297963)
22. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fi brillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest . 2004;12 6( 3 Suppl ) :429S-56S. (Pubitemid 39302603)
23. Marcucci M, Iorio A, Nobili A, Tettamanti M, Pasina L, Marengoni A, et al. Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. Eur J Intern Med. 2010;21:516-23.
24. Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs. Chest. 2008;133:234S-56S.
25. Haas S. Rivaroxaban - an oral, direct factor Xa inhibitor: lessons from a broad clinical study programme. Eur J Hae-matol. 2009;82:339-49.
26. Dubois EA, Cohen AF. Dabigatran etexilate. Br J Clin Pharmacol. 2010;70:14-15.
27. Bauer KA. New anticoagulants. Hematology Am Soc Hema-tol Educ Program. 2006:450-6.
28. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al.; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, noninferiority trial. Lancet. 2007;370:949-56. (Pubitemid 47393577)
29. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al.; RE-MODEL Study Group. Oral dabigat-ran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the REMODEL randomized trial. J Thromb Haemost. 2007;5:2178-85. (Pubitemid 47617868)
30. Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, et al.; RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24:1-9.
31. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al.; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthro-plasty. N Engl J Med. 2008;358:2765-75. (Pubitemid 351930851)
32. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, et al.; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008; 372:31-9.
33. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al. Rivaroxaban versus enoxaparin for throm-boprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776-86. (Pubitemid 351930852)
34. Turpie AG, Bauer KA, Davidson B. Comparison of rivar-oxaban, an oral direct Factor Xa inhibitor, and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement (RECORD 4: a phase III study). 2008: Proceedings of the 9th EFORT Congress; 30 May 2008; Nice, France. Abstract F85.
35. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al.; and the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fi brillation. N Engl J Med. 2009;361:1139-51.
36. Mannucci PM, Franchini M. New anticoagulants in internal medicine: an update. Eur J Inter Med. 2010;21:466-7.
37. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al.; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous throm-boembolism. N Engl J Med. 2009;361:2342-52.
38. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood. 2010;115:15-20.